AMGN Stock Recent News

In today's unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those that don't rely too heavily on international markets.

Amgen Inc. (NASDAQ:AMGN ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations James Bradner - EVP, Research & Development Peter Griffith - EVP & CFO Conference Call Participants Terence Flynn - Morgan Stanley Salveen Richter - Goldman Sachs Michael Yee - Jefferies Trung Huynh - UBS Evan Seigerman - BMO Capital Markets Chris Schott - JPMorgan Yaron Werber - TD Cowen Umer Raffat - Evercore ISI David Amsellem - Piper Sandler Jay Olson - Oppenheimer Gregory Renza - RBC Capital Markets Matt Phipps - William Blair Alex Hammond - Wolfe Research Operator My name is Julianne and I'll be your conference facilitator today for the Amgen Q1 FY 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amgen (AMGN) came out with quarterly earnings of $4.90 per share, beating the Zacks Consensus Estimate of $4.16 per share. This compares to earnings of $3.96 per share a year ago.

Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales increased 11% and profit margins widened.

THOUSAND OAKS, Calif. , May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025.

While the strategy involves buying the Dogs of the Dow at the start of January, there are a few still worth betting on as markets regain lost ground.

Reliable dividend income from high-quality companies is a great option for investors seeking to ride out stock market turbulence. Biotech giant Amgen (AMGN 0.82%) exemplifies this strategy with its 3.3% dividend yield, supported by steady growth and rock-solid fundamentals.

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Volume growth of AMGN's key drugs like Evenity, Repatha and Kyprolis is expected to have been partially offset by biosimilar/generic competition for mature drugs.